Bipolar affective disorder is a severe mood disorder that afflicts approximately 1% of the population worldwide. Twin and adoption studies have indicated that genetic factors contribute to the disorder and while many chromosomal regions have been implicated, no susceptibility genes have been identified. In this present study, we undertook a 10 cM genome screen using 400 microsatellite markers in a large multigenerational bipolar pedigree consisting of 40 individuals, including six affecteds. We found strongest evidence for linkage to chromosome 13q14. A maximum NPL score of 4.09 (P = 0.008) was obtained between markers D13S1272 and D13S153 using GENEHUNTER. A maximum two-point LOD score of 2.91 ( = 0.0) was found for marker D13S153 and a maximum three-point LOD score of 3.0 was obtained between markers D13S291 and D13S153 under a recessive model with 90% maximum age-specific penetrance and including bipolar I and unipolar individuals as affected. Several other markers in the region, D13S175, D13S218, D13S263, and D13S156 had two-point LOD scores greater than 1.5. These results meet the criteria for evidence of suggestive linkage. Haplotype analysis enabled us to narrow the likely disease region to a 6 cM region between markers D13S1272 and D13S1319, which contains the serotonin 2A receptor candidate gene. Two single nucleotide polymorphisms were identified in this gene but we did not detect any significant differences in allele frequency in a case-control sample. The region on chromosome 13q14-32 has previously been implicated in other bipolar and schizophrenia cohorts. Our results provide further support for the existence of a susceptibility locus on chromosome 13q14. Molecular Psychiatry (2001) 6, 396-403.
Introduction
Bipolar affective disorder (MIM 125480) is a severe mood disorder characterised by alternating periods of mania and depression. Bipolar disorder afflicts approximately 1% of the population worldwide 1 and is the sixth highest cause of disability globally. 2 The etiology of bipolar disorder remains unknown. Twin and adoption studies have indicated that genetic factors contribute to the disorder. 3, 4 While the number of genes and the mode of transmission of bipolar disorder is unclear, identification of the genes involved in the disorder has been the focus of much research over the past decade.
While many chromosomal regions have been implicated in bipolar disorder, the most compelling evi-dence for linkage of bipolar disorder to a genetic locus has come from studies of large multigenerational pedigrees, having identified regions on chromosomes 21, 5 
12
6 and 4. 7, 8 In a single large pedigree from a cohort of 47 bipolar pedigrees, a possible susceptibility locus at the phosphofructokinase (PFKL) locus on 21q was identified with a LOD score of 3.41 ( = 0) under a dominant model of inheritance. 5 Since this report several other groups have found substantial support for linkage to this region. [9] [10] [11] [12] [13] Similarly, a single large pedigree from a cohort of UK pedigrees gave a LOD score of 4.1 ( = 0) under a dominant model of inheritance at D4S394 on chromosome 4p. 7 We have previously identified evidence for a locus on chromosome 4q35 in a large multigenerational pedigree with a LOD score of 3.2 using a dominant model of inheritance. 8 Support for the 4q35 locus has also been observed in other pedigree cohorts. 14 In 1994, Craddock et al identified a pedigree cosegregating for bipolar disorder and Darier's disease, raising the possibility that the 12q23-q24 region encoded a potential bipolar disorder susceptibility locus. 6, 15 While not confirmed in genome screens of pedigree cohorts, 16 ,17 studies of a very large French Canadian pedigree 18 and two Danish pedigrees 19 have provided significant evidence for linkage to this region.
Recently, linkage studies of bipolar disorder have indicated the existence of a susceptibility locus on chromosome 13q. A high-density genome scan in 22 US pedigrees found evidence for linkage to 13q31-32, with a LOD score of 3.5 (P = 0.000028) between D13S1252 and D13S1271. 20 Support for a locus on 13q was seen in a genome scan in the Old Order Amish. 21 In the Old Order Amish study, marker D13S1 gave a P = 0.0003 under SIBPAL analysis and markers D13S1 and D13S218 gave multipoint LOD scores of 1.42 and 1.5, respectively. 21 Similarly a genome scan of the 97 families from the NIMH Genetics Initiative Bipolar Group showed positive evidence for linkage to 13q14-32 under two methods of analysis. 22 Excess allele sharing in affected sib pairs was observed for two markers D13S800 (P = 0.04) and D13S793 (P = 0.02). The maximum LOD scores obtained by nonparametric multipoint analysis were 1.12 at D13S793 and 0.5 at D13S800. 22 In this present study we report the results of a genome screen in a new large multigenerational pedigree. Analysis from this genome screen provides support for the existence of a bipolar disorder susceptibility locus on chromosome 13q.
Subjects and methods

Family ascertainment
The family was ascertained as part of an ongoing bipolar genetics study via the Mood Disorders Unit, Prince of Wales Hospital/University of New South Wales, Sydney, Australia. Medium to large multigenerational pedigrees were recruited, with illness over at least two generations and containing a minimum of three affected individuals, two of whom were diagnosed with bipolar I. Families were Caucasian and almost entirely of British descent. The families were assessed using the Diagnostic Interview for Genetic Studies (DIGS) 23 and best-estimate Research Diagnostic Criteria diagnoses were made after independent evaluation of interviews and medical records. All marryingin individuals were routinely questioned about any family history of psychiatric illness to ensure unilateral descent of bipolar in the pedigrees. Individuals who participated in the study provided appropriate informed written consent.
The family used in this study contained 58 individuals with 40 available for analysis which included six affecteds; four with bipolar I (BPI) and two with recurrent unipolar depression (UP) (Figure 1 ). Simulation analyses using SLINK and MSIM 24, 25 were carried out in order to determine the power of this pedigree to detect linkage. Using a dominant model of inheritance with 90% maximum age-specific penetrance, a 6-allele marker and including BPI and UP individuals as affected, the maximum expected LOD scores for this pedigree under the assumption of linkage and no linkage were 3.5 and 0.29, respectively.
Molecular Psychiatry
Genotyping DNA was extracted from whole blood using a standard salting-out method. All samples were genotyped with 400 microsatellite markers from the ABI PRISM Linkage Mapping Set Version 2. The markers in this mapping set had an average heterozygosity of 0.79 and were spaced at approximately 10 cM across the genome. Genotyping was carried out at the Australian Genome Research Facility, Melbourne, Australia (www.agrf. org.au). Additional microsatellite markers analysed on chromosome 13q14 were obtained from the Genome Database (GDB) and included D13S221, D13S1248, D13S1272, D13S291, D13S1319, D13S777, D13S1218 and D13S1257.
PCR of the additional markers was carried out in 15 l volume containing 60 ng DNA, 250 M dNTPs, 0.33 M of each primer (the forward primer labelled with 6-FAM fluorescent dye), 2.5 mM MgCl 2 , 1 × PCR buffer (PE Applied Biosystems, Foster City, CA, USA) and 0.6 units AmpliTaq Gold polymerase (PE Applied Biosystems). PCR reactions were carried out on a Hybaid OmniGene thermal cycler using the following protocol; 95°C for 12 min, 30 cycles of 95°C for 30 s, either 58°C or 60°C for 30 s, 72°C for 30 s, 72°C for 5 min. The PCR product (1.5 l) was mixed with loading dye (2.5 l formamide, 0.5 l of 50 mg ml −1 blue dextran: 50 mM EDTA, 0.5 l GeneScan500 Tamra size standard (PE Applied Biosystems). Samples were loaded onto a 4% polyacrylamide gel and electrophoresis was carried out on a ABI PRISM 377 DNA Sequencer (PE Applied Biosystems). Products were detected using the GeneScan Analysis program, version 3.1 (PE Applied Biosystems) and alleles were assigned using the Genotyper program, version 2.5 (PE Applied Biosystems).
Linkage analysis
The ANALYZE package 26 was used to automate twopoint LOD score analysis. Parametric multipoint analysis was performed using LINKMAP of the LINKAGE Package, version 5.2. 27 Non-parametric multipoint analyses were performed using GENEHUNTER. 28 Two disease thresholds were used in the analysis. In the narrow disease model, individuals diagnosed with BPI were classified as affected and all other family members were classified as unaffected. In the broad disease model, individuals diagnosed with either BPI or UP were classified as affected and all other family members were considered unaffected. Four liability classes (class 1, Ͻ20 years; class 2, 20-29 years; class 3, 30-39 years and class 4, Ͼ40 years) were used in the analysis with maximum age-specific penetrance levels of either 60% or 90%. In the 90% model, liability classes were defined with penetrances of 0.18, 0.45, 0.68 and 0.9; those in the 60% model were defined with penetrances of 0.12, 0.30, 0.45 and 0.6. The data was analyzed under both dominant and recessive inheritance models. The disease-allele frequency was set at 0.035 for the dominant model and 0.2 for the recessive model, and a phenocopy rate of 5% was used in all analyses. Allele frequencies were calculated from the data using the DOWNFREQ program from the ANA-LYZE package 26 using all individuals. Recombination fractions were converted from centimorgan distances provided on the ABI/CHLC integrated map (http://lpg.nci.nih.gov/html-chlc/ChlcMaps.html).
Candidate gene analysis
Three BPI individuals and their unaffected spouses from the family were screened, via direct sequencing, for single nulceotide polymorphisms (SNPs) in the serotonin receptor 2A (HTR2A) gene using 11 pairs of overlapping primers spanning the coding region and intron-exon boundaries as described in Erdmann et al. 29 The primers used were: 5-HT2A-1F, TCAAGG TGAATGGTGAGCAG; 5-HT2A-1R, GGCACCCTTCAC AGGAAAG; 5-HT2A-2F, AATGATGACACCAGGCTCT ACA; 5-HT2A-2R, TAGTTGGTGGCATTCTGCAG; 5-HT 2A-3F, ACTCGTCATCATGGCAGTGTCCCT; 5-HT2A-3R, GTTTGTTTGCCCCCGGAGCC; 5-HT2A-4F, GGAT AGGGATCCATGTGCTC; 5-HT2A-4R, TGTGGTGGAT GGGATTCTG; 5-HT2A-5F, ATCTCGCTGGACCGCTAC; 5-HT2A-5R, CAGTAGATTGAGGATGTCAGG; 5-HT2A-6F, TGATGATGCTCTTGCCTTCA; 5-HT2A-6R, GTGATCA CCATGATGGTTAAGG; 5-HT2A-7F, CATGCCAATAC CAGTCTTTGG; 5-HT2A-7R, TGAGGGAGGAAGCTG AAAGA; 5-HT2A-8F, TGTAAGTGATCTTGGCACACG; 5-HT2A-8R, AAGAAAGGGCACCACATCAC; 5-HT2A-9F, GTCCATCAGCAATGAGCAAA; 5-HT2A-9R, CGTG AAAAGGCTGACCTATAGG; 5-HT2A-10F, ATCTCTCTT CAGCAGTCAACCC; 5-HT2A-10R, GAGCAACCATTG AGCAGTCA; 5-HT2A-11F, CAAAGCAAGATGCCAAG ACA; 5-HT2A-11R, GGCATACAGATATGATCGTTGG.
To screen the gene for variation, PCR amplified products were purified using QIAGEN QIAquick PCR Purification columns (QIAGEN, Hilden, Germany). DNA cycle sequencing was performed on a Hybaid OmniGene thermal cycler using the ABI PRISM BigDye Terminator Ready Reaction Kit, 50 ng PCR product and the following protocol; 25 cycles of 95°C for 30 s, 50°C for 15 s, 60°C for 4 min. Products were loaded onto a 4% polyacrylamide gel and electrophoresis was carried out on a ABI PRISM 377 DNA Sequencer (PE Applied Biosystems). Products were detected using the Sequencing Analysis program, version 3.3 (PE Applied Biosystems). Base changes were detected using the AutoAssembler program, version 2.1 (PE Applied Biosystems).
In order to determine if SNP variation identified in the HTR2A gene was associated with bipolar disorder in our population as a whole, a limited case-control sample was selected from our pedigree cohort in order to compare allele frequencies between affected individuals and unaffected individuals. The case-control sample consisted of 27 affected individuals and their unaffected spouses (n = 27), with each pair coming from a separate pedigree in our cohort. Differences in genotype and allele frequencies between cases and controls were compared using 2 analysis. For genotyping of the SNPs in the case-control population, RFLP assays were used. After amplification of genomic DNA, 10 l of PCR product were digested with either 5 U of MspI or 5 U of BbvI according to manufacturer's recommendations. Digested products were separated on a 2% high resolution agarose gel and visualised using ethidium bromide. Figure 2 shows the maximum two-point LOD scores across the genome obtained for the 90% maximum agespecific penetrance models for both dominant and recessive models of inheritance and for both the narrow and broad disease definitions (data for the 60% maximum age-specific penetrance models are not shown). Two-point LOD scores greater than 1.5 were obtained for six markers across the genome, five markers on chromosome 13q11-21 and one marker on chromosome 3q21-25. The strongest evidence for linkage was on chromosome 13q14, with a genome-wide maximum LOD score of 2.91 at D13S153 under a 90% recessive model, for the broad disease definition. Several other markers in the region on 13q11-21 also gave LOD scores greater than 1.5; D13S175, 1.55; D13S218, 2.07; D13S263, 2.12 and D13S156, 1.5 (Table 1) . Parametric multipoint analysis gave a maximum threepoint LOD score of 3.0 between markers D13S291 and D13S153 under the same model.
Results
Identification of a potential susceptibility locus on 13q14
In this analysis no positive LOD scores were obtained under the dominant model with either 60% Molecular Psychiatry or 90% maximum penetrance for the 13q14 markers. However, reducing the maximum age-specific penetrance to 30%, under a dominant model, gave a LOD score of 1.08 for D13S153. Similarly, affecteds only analysis gave LOD scores of 1.0 under both dominant and recessive models. This suggests that unaffected individuals are contributing to the analysis and that bipolar disorder in this family can not be explained by either a simple dominant or simple recessive model of inheritance. Consequently, in the absence of a clear genetic model, a nonparametric form of analysis of these data may be more appropriate. Nonparametric analysis using GENEHUNTER gave a maximum NPL score of 4.09 (P = 0.008) at D13S153 (Figure 3 ), providing strong support for the LOD score results. The only other marker giving a LOD score greater than 1.5 was D3S1292 on 3q21-25 which had a value of 1.55 under a 60% dominant model for the narrow disease definition (Table 1) . LOD scores greater than 1.0 were also obtained for three other markers on 3q21-25; D3S1278, D3S1279 and D3S1569 under both dominant and recessive models. LOD scores between 1.0 and 1.5 were also obtained for two markers on chromosome 5q35; D5S400 and D5S408 and two markers on chromosome 9q33; D9S1776 and D19S571.
Haplotype analysis of 13q14 markers
An additional nine microsatellite markers on chromosome 13q11-14 were genotyped in this pedigree giving a denser marker map of the region, with an average intermarker distance of 3.5 cM and spanning approximately 43 cM on chromosome 13q11-14. Marker haplotypes were constructed to identify a disease haplotype and to determine if there were any recombination events that could narrow the region of linkage. All individuals diagnosed with either BPI or UP carry a common haplotype that segregates with the disorder (Figure 4) . Furthermore, as a result of recombination events in individuals II:1, II:4, II:5, II:9, II:11, II:13, II:15 and III:17, the only portion of the disease haplotype shared by all affected individuals is defined by two markers, D13S291 and D13S153. In generation II, all affected individuals share the same portion of both chromosomes, while individuals III:24 and IV:6 share the same portion of a single chromosome. This narrows the area of interest to an approximately 6 cM region between markers D13S1272 and D13S1319. There are also three unaffected members of this pedigree who carry part of the chromosome 13q14 haplotype. Unaffected individual II:5 carries a region distal to D13S1272, while unaffected individuals II:9 and II:15 carry a region of the haplotype proximal to marker D13S218 (Figure 4 ). There were no recombination events in either individuals II:7 or II:10.
The serotonin 2A receptor candidate gene analysis
The serotonin 2A receptor is a neurotransmitter receptor that mediates many sensory, motor and cortical functions. Disturbances in the serotonergic pathways have been implicated in many psychiatric disorders including bipolar disorder. As the gene for the serotonin 2A receptor (HTR2A) is located between D13S153 and D13S1319 on 13q14 and is in the region covered by the disease haplotype, we assessed the gene as a possible candidate for bipolar disorder in this family. Screening of six individuals (three affecteds and three unaffecteds) from the family by direct sequencing identified two SNPs in the HTR2A gene. Both variants have previously been identified in other populations. 30 The first is a T to C base change at nucleotide +102, which is a silent mutation, and the second a C to T base change at +1354 which results in a His452Tyr amino acid substitution. No novel sequence variants were detected in this family.
The T to C base change at +102 results in the gain of a MspI restriction site. Amplification of genomic DNA with primers 5-HT2A-1F and 5-HT2A-1R and subsequent digestion with MspI results in a 257-bp fragment for the 102T allele, and 177-bp and 80-bp fragments for the 102C allele. The C to T base change at +1354 results in the loss of a BbvI restriction site. Amplification of genomic DNA with primers 5-HT2A-11F and 5-HT2A-11R, and subsequent digestion with BbvI results in 180-bp and 68-bp fragments for the 1354C allele and a 248-bp fragment for the 1354T allele. We determined the genotypes of the +102 and +1354 polymorphisms in the rest of the family and analysed these data by linkage analysis. Both polymorphisms gave positive two-point LOD scores under a recessive model of inheritance; the +102 polymorphism gave a LOD score of 0.98 and the +1354 polymorphism gave a LOD score of 0.5. Five of the six affected individuals were homozygous for the +102T allele and +1354C allele.
In order to assess if these base changes were associated with bipolar disorder in a larger population cohort, we determined the genotypes of the +102 and +1354 polymorphisms in a limited case-control cohort consisting of 27 affected individuals (one from each of the other pedigrees in our cohort) and their unaffected spouses. The distribution of the +102 and +1354 genotypes and alleles, in the cases and controls, are shown in Table 2 . There was no significant difference in the frequency of either the genotypes or the alleles at either +102 or +1354 in cases as compared to controls.
Discussion
We have identified, from a genome screen of a large Australian pedigree segregating for bipolar disorder, evidence for linkage to chromosome 13q14. A NPL score of 4.09 (P = 0.008) was obtained between markers D13S1272 and D13S153, a maximum two-point LOD score of 2.91 ( = 0.0) was found for marker D13S153 and a maximum three-point LOD score of 3.0 was obtained between markers D13S291 and D13S153. Multiple consecutive markers on 13q14 also gave twopoint LOD scores above 1.5 in this family. It has been shown that positive LOD scores for consecutive markers across a region are a good indicator of loci associated with complex disorders. 31 In addition, the markers on 13q14 were the only markers across the genome to give scores greater than 2.0. While the LOD scores obtained for the 13q14 markers vary with the genetic model analysed, the nonparametric analysis results provide additional support for a susceptibility locus on 13q14. These results are consistent with evidence for suggestive linkage according to the criteria proposed by Lander and Kruglyak. 32 Haplotype analysis enabled us to narrow the shared region between affected individuals in the family to a 6 cM region between markers D13S1272 and D13S1319, containing the HTR2A candidate gene. Screening of the HTR2A gene in our pedigree identified two common polymorphisms seen in other popu- Figure 4 Haplotype analysis for the family using 16 microsatellite markers with an average intermarker distance of 3.5 cM on chromosome 13q14. The pedigree has been simplified to show only individuals carrying the disease haplotype or a portion of the disease haplotype. The disease haplotypes are shown as boxed allele numbers. All affected individuals carry a common haplotype (II:4, II:11, II:13, II:17, III:24 and IV:6) and recombination events narrow the shared region among affecteds to 6 cM between markers D13S1272 and D13S1319. Affected individuals in the second generation share the same portion of both chromosomes and affected individuals III:24 and IV:6 share the same portion of one chromosome. lations; the T to C base change at +102 and the C to T base change at +1354. 30, 33 Both the +102 and +1354 polymorphisms gave positive LOD scores in this pedigree and five of the six affected individuals from the family were homozygous for the +102T allele and the +1354C allele, which is consistent with the most positive LOD scores for 13q14 being obtained under a recessive inheritance model. However, we found no association between these polymorphisms and bipolar disorder in a limited case-control sample derived from our larger pedigree cohort. The lack of association between polymorphisms of the HTR2A gene and bipolar disorder in our study could be due to the relatively small number of cases and controls analysed. However, the variation in a gene associated with bipolar disorder may also differ between families, with association studies of individual base changes consequently being unable to identify any one possible variant responsible for susceptibility to the disorder. It is possible that a regulatory variant conferring disease susceptibility in this study is yet to be identified and therefore the HTR2A gene cannot be excluded as a candidate for bipolar disease in this pedigree.
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The region implicated on chromosome 13 at 13q14 in this study, 13q14-32 in Detera-Wadleigh et al 20 and Stine et al 22 and 13q13 in Ginns et al, 21 is broad and the markers are separated by approximately 10-25 cM. Simulation studies have indicated that there is a large degree of variation in location estimates, with 95% confidence intervals covering as much as 30 cM for a typical complex trait with 200 affected sib pairs. 34 In addition, at loci where the proportion of sibs sharing alleles is Ͻ0.6, as observed in Stine et al, 22 it may be expected that the gene will lie outside the range of maximal sharing. 32 Given these observations, it is possible that the regions identified by the above studies and our own study are the same.
The region on chromosome 13q32 has also been implicated as a susceptibility locus for schizophrenia. A maximum three-point LOD score of 4.42, under heterogeneity (␣ = 0.65), was found for D13S793 in a cohort of moderate-sized Canadian pedigrees, providing evidence of significant linkage of this region to schizophrenia. 35 The above study also provided independent confirmation of previous reports of linkage of schizophrenia to 13q14-32. 36, 37 This region overlaps with the region implicated in studies of bipolar disorder. 20, 22 In addition, a recent study identified linkage of panic disorder to the same region on chromosome 13. 38 These findings suggest that the region may harbour a common susceptibility gene or genes relevant to psychiatric illness in general.
It is not difficult to find reasons for the lack of identification of, and replication of linkage to, loci conferring susceptibility to bipolar disorder. Given that the pathophysiology of the disorder is unknown, the field has had to rely on diagnosis and phenotypic classification based solely on clinical criteria. In addition, the underlying genetic mechanisms involved in bipolar disorder are unknown. Clearly the number of possible susceptibility loci identified to date provide strong evidence that bipolar disorder is multigenic and subject to genetic heterogeneity. If there is significant heterogeneity, this could explain the failure of genome screens of large cohorts of smaller-sized pedigrees 14, 39 to identify loci that meet the criteria for a initial finding of significant linkage, due to multiple independently segregating susceptibility loci. Conversely, genome screens of large multigenerational pedigrees have provided the most compelling evidence for linkage of bipolar disorder to a locus. The most likely explanation for this is that within a single large pedigree, where the locus is of modest effect, the other susceptibility loci could be largely homozygous, such that one is able to observe evidence for linkage for that single segregating locus.
The results of this genome screen and subsequent high-density mapping of a large bipolar disorder pedigree have identified a potential susceptibility locus located within a 6 cM region on chromosome 13q14. Our results provide support for other studies that have identified this region in either bipolar disorder or schizophrenia pedigrees. This region includes the HTR2A gene as well as the Esterase D (ESD), ATPase, Cu 2+ transporting ␤ polypeptide (ATP7B), lymphocyte cytosolic protein 1 (LCP1) and retinoblastoma (RB1) genes. The eventual identification of the allelic variation that leads to this susceptibility locus should provide a means by which the molecular basis of these severe psychiatric disorders can be defined and understood.
